Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246610 · ClinicalTrials.gov registry record · Phase 4
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT00246610 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT00246610, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT
Interventions
- DRUG Nelfinavir mesylate, 625 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246610
The ClinicalTrials.gov registry entry for NCT00246610 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir mesylate, 625 mg is the first listed.
NCT00246610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246610 about?
NCT00246610 is a clinical study titled "Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy". This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT
What is the current status of trial NCT00246610?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2006-03. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00246610?
The interventions under investigation include: Nelfinavir mesylate, 625 mg (DRUG).
Who is sponsoring clinical trial NCT00246610?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.